Evaluation of GenoType MTBDRplus for the detection of drug-resistant Mycobacterium tuberculosis on isolates from Karachi, Pakistan.
Antitubercular Agents
/ pharmacology
Bacterial Proteins
/ genetics
DNA-Directed RNA Polymerases
/ genetics
Genotype
Humans
Isoniazid
/ pharmacology
Male
Microbial Sensitivity Tests
Mutation
Mycobacterium tuberculosis
/ genetics
Pakistan
Rifampin
/ pharmacology
Tuberculosis, Multidrug-Resistant
/ genetics
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
04
2019
accepted:
07
08
2019
entrez:
20
8
2019
pubmed:
20
8
2019
medline:
4
3
2020
Statut:
epublish
Résumé
To compare the diagnostic performance of the GenoType MRBDRplus assay with the gold standard phenotypic drug susceptibility testing in the detection of drug resistance among culture isolates obtained from patients in Karachi, Pakistan. Mycobacterium tuberculosis isolates were obtained from 96 consecutive tuberculosis patients found to have resistance to isoniazid from two health centers in Karachi (January-November 2017). Isolates were tested for drug resistance against rifampin and isoniazid using the MTBDRplus assay. Results were compared with conventional drug-susceptibility testing and the frequency of specific mutations were reported. The MTBDRplus assay had a sensitivity for rifampin resistance of 98.8% (95% CI: 93.4-100) and for isoniazid resistance of 90.6% (95% CI: 83.0-95.6). The MTBDRplus assay showed mutations in rpoB in 81 of the 96 (84.4%) isolates. Of the 87 isolates showing resistance to isoniazid via the MTBDRplus assay, 71 (74.0%) isolates had mutations in the katG gene only, 15 (15.6%) isolates had mutations in the inhA promoter region, and 1 (1.0%) showed mutations in both genes. The GenoType MTBDRplus assay in Pakistan can identify subgroups at high-risk of having isolates with mutations in the katG and/or inhA genes. Understanding the local burden of these mutations have implications for local diagnostic and treatment guidelines.
Identifiants
pubmed: 31425565
doi: 10.1371/journal.pone.0221485
pii: PONE-D-19-09472
pmc: PMC6699735
doi:
Substances chimiques
Antitubercular Agents
0
Bacterial Proteins
0
rpoB protein, Mycobacterium tuberculosis
0
DNA-Directed RNA Polymerases
EC 2.7.7.6
Isoniazid
V83O1VOZ8L
Rifampin
VJT6J7R4TR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0221485Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Clin Microbiol. 2006 Jan;44(1):20-8
pubmed: 16390942
J Clin Microbiol. 2006 Jul;44(7):2338-42
pubmed: 16825346
Eur J Clin Microbiol Infect Dis. 2007 Mar;26(3):203-5
pubmed: 17294161
J Clin Microbiol. 2007 Aug;45(8):2635-40
pubmed: 17537937
Annu Rev Microbiol. 2007;61:35-50
pubmed: 18035606
Int J Tuberc Lung Dis. 2008 Feb;12(2):139-45
pubmed: 18230245
BMC Infect Dis. 2009 May 20;9:67
pubmed: 19457256
Antimicrob Agents Chemother. 2011 Dec;55(12):5654-9
pubmed: 21911575
Int J Tuberc Lung Dis. 2013 Jan;17(1):129-30
pubmed: 23146620
J Clin Lab Anal. 2013 Jan;27(1):31-7
pubmed: 23325741
J Antimicrob Chemother. 2013 Aug;68(8):1728-32
pubmed: 23539241
J Glob Infect Dis. 2015 Apr-Jun;7(2):60-5
pubmed: 26069424
Int J Tuberc Lung Dis. 2016 Aug;20(8):1099-104
pubmed: 27393546
Infect Genet Evol. 2016 Nov;45:474-492
pubmed: 27612406
Front Microbiol. 2018 Sep 26;9:2265
pubmed: 30319577
J Clin Microbiol. 1997 Mar;35(3):719-23
pubmed: 9041419